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Abstract 
I propose an asymmetric stopping rule which allows the 
experimenter to terminate a clinical trial early for a sufficiently 
negative ~esult and to continue to a specified number of patients 
otherwise. If interim data are positive we are willing to wait in 
order to measure the various safety factors. A sufficiently 
negative interim result will terminate the trial to either (1) 
minimize exposure to an apparently inferior treatment, or (2) cut 
the losses of a pharmaceutical company whose product is inferior~ 
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1. INTRODUCTION 
In many clinical trials that compare two treatments on the 
basis of short-term measures of effectiveness, the data are reviewed 
periodically to identify any trends which may suggest early 
termination. One possibility is the repeated application of 
standard statistical tests with the usual critical values. However, 
when the null hypothesis is true, the probability of obtaining a 
"significant" outcome at least once during a sequence of such tests 
is substantially higher than the nominal significance level (see 
Armitage~ Mcpherson & Rowe (1969)). Pocock (1977) suggests a larger 
constant critical value for each test, the maximum number of such 
tests being specified in advance. O'Brien and Fleming (1979) 
suggest being very conservative early by using large critical values 
and decreasing the nominal critical value during the course of the 
trial so that the actual level is close to the nominal level at the 
test scheduled at the end of the trial. Lan and DeMets (1983) have 
shown how to use these methods without having to specify the number 
of tests in advance but only the form of boundary. Demets and Ware 
(1980) also consider three possible modifications of the group 
sequential method for sequential monitoring of clinical trials 
testing a one-sided hypothesis. Another approach which incorporates 
a "range of equivalence" into a formal stopping rule for the trial 
using an extension of the group sequential design has been recently 
discussed by Freedman, Lowe and Macaskill (1984). 
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There are many trials in which the investigator(s) would not be 
willing to stop the trial on the basis of superior efficacy of the 
treatment. For this would result in limited information regarding 
safety considerations (as well as for secondary efficacy 
measurements). For example, few if any trials sponsored by 
pharmaceutical companies would be stopped on the basis of favorable 
efficacy. Regulatory agencies require that the drug be used on a 
reasonably large number of patients so that serious adverse 
experiences with moderately low incidence rates can be detected. 
I propose a design which allows the drug developer to terminate 
the development program early if the new drug is not efficacious and 
to continue the trial to a specified number of patients as long as 
the results are positive. So if accumulating data show a benefit, 
the trial (program) will continue so that information concerning the 
various safety factors will accrue. But if interim data are 
sufficiently negative then the trial will end early, thus minimizing 
ineffective treatment and saving resources that can be better 
allocated elsewhere~ Clearly, the objectives of the one-sided 
stopping rules proposed here are quite different from those 
suggested by Demets and Ware (1980)~ The major question that is 
addressed in this paper is: how negative need the results be before 
the trial should be stopped? 
2. PROPOSED DESIGN 
Suppose that a clinical trial is performed to compare a new 
treatment T to a control C with respect to mean outcome on a 
continuous response variable. Assume that the treatment response 
· 2 2 · 
variable XT - N(µT,a) and the control variable is XC - N(µC,a ). 
Following the group sequential test of Pocock ( 1977); the data are 
tested after every equally divided group of 2n patients is entered, 
up to a maximum of N groups of subjects. Assume a2 is known~ This 
assumption is not very restrictive when n is moderately large. 
Let µT - µc = o. Consider testing 
H0 : o ~ 0 vs. HA: o > O. 
At the mth stage, we shall use as test statistic, 
m 
d = l (t. - c. )/m, 
m j=1 J J 
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where tj and cj represent the observed mean responses for treatments 
T and C, respectively, in the jth subsample or "group". That is, 
and 
where tj 1, ••• , tjn are then responses of jth group with treatment 
T and the cjk' s are those with treatment C. For m ~ 1 ~ ~ ~ ~ ~ N; 
define 
Consider the following testing procedure: 
Stop the trial at stage m and decide that Tis not 
effective (i.e., accept H0) if z ~ b (m = 1, m m . . . ' N-1) • 
If Z > b then take the next subsample and repeat the 
m m 
process. If testing reaches the Nth stage, reject 
H0 if ZN> bN and accept otherwise. 
The sequence {b1 , -~~~ bN} is chosen to have appropriate total 
rejection probabilities. 
3. CONSTANT NOMINAL SIGNIFICANCE LEVEL 
A simple version of the boundary defined in Section 2 is given 
by 
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A design with this boundary has a constant nominal significance 
level. For given overall significance level, it can be difficult to 
calculate bN. It is relatively straightforward, however, to find a 
bound for bN. One is given in the next theorem. The theorem says 
that a conservative procedure is to ignore the interim analyses! 
Theorem 1 If the overall type I error. is a then bN ~ za for all a, 
where t(z) = 1 - a~ 
a 
Proof: 
a = Pr { Z > b , m = 1 , ••• , N I c5 = 0 } 
m m 
= Pr{zN > bNlcS=O}Pr{zm > bm' m = 1, ••• , .. N-~ IZN > bN~ c5=0} 
= [1 - ~(bN)]Pr{zm > bm' m = 1, ••• , N - 1IZN > bN' o=O} 
===> ~(bN) ~ ~(za) ===> bN ~ za. a 
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For a two-sided symmetric test as discussed in Section 1~ if 
one continually tests accumulating data for "significant results", 
one could eventually reach nominal significance by chance alone. 
Using the same conventional critical value at each test will raise 
the type I error beyond the nominal level associated with the 
critical value. The degree of this increase depends in part on the 
number of tests. For example, suppose one uses a conventional ±1~96 
critical value associated with a 5 percent significance level for a 
single test~ After five tests the type I error would be ~142 (see 
Armitage et al., 1969) and would be considered unacceptable~ Thus, 
some adjustment is necessary for the symmetric boundaries described 
in Section 1. Theorem 1 says that proceeding with no adjustment is 
conservative in the one-sided case. 
To calculate exact sizes of the tests I used numerical methods 
based on Armitage et al. (1969) and Pocock (1977)~ Table 1 shows 
the actual type I errors if the conventional critical values were 
used. For the tabled values the differences between the actual and 
' nominal levels with a = .01 or .05 are negligible. That is, for 
the one-sided test proposed here~ the conclusions of the trials are 
almost independent of the number of interim analyses performed if a 
is small and N is not too large. This is quite different from the 
two-sided symmetric setting in which the conclusions are markedly 
dependent on the stopping rule. 
TABLE 1 
The actual size a for the test with bN=za, the 
conventional critical value corresponding to a' 
N a' bN a 
2 • 01 2.3263 .0100 
.05 1. 6449 .0499 
• 1 1.2816 .0999 
3 • 01 2~3263 .0100 
.05 1 ~ 6449 .0499 
• 1 1 ~ 281 6 .0996 
4 • 01 2.3263 .0100 
.05 1. 6449 .0499 
• 1 1.2816 .0990 
5 • 01 2~3263 .0100 
.05 1.6449 .0499 
• 1 1. 2816 .0986 
4~ GROUP SIZE DETERMINATION 
The group size 2n is independent of the size of the test and 
thus the calculation of the boundaries~ However, the group size 
plays an important role when the power of the test is considered. 
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Following Pocock (1977), let n = 2(.Aa/o) 2 (i.e. fl= o./n/a./2)~ so 
that it is convenient to express o ,-in terms of a. Tables 2 to 5 
show the suitable value of n given N, a, o and power n. The value 
of n will need to be rounded off resulting in a slight change inn; 
this difference should be negligible in practice. As an example of 
these tables suppose a= .05, o = .5a and n = .9. Then for N = 3 
groups, fl= 1.69 from Table 4~ so that the required number of 
. . 2 ,. 
patients per group is 2n = 4x{1.69/0.5) = 45.7 and the maximum 
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number of patients for the whole trial is 2nN = 46x3 ~ 138~ This is 
not exact since n has been rounded to an integer, but the error is 
slight. Another interesting result is suppose a= .01 and n = .95, 
then Tables 2 to 5 say that the required number 2n of patients per 
group is 63~1, 31 ~5, 21 ~O~ 15.8 for N = 1 to N = 4 respectively. 
Hence~ if we multiply 2n by N correspondingly this gives 
approximately the same value: 63~1~ In other words, if one fixes a 
and n then the subgroup size 2n for a design with N = k is 
approximately equal to the total sample size corresponding to a 
one-sided fixed sample test (i~e~, N = 1) divided by k~ 
5. THE ROLE OF a 
The appropriate design of a trial depends among other factors 
on its purpose, the availability or patients~ and costs. In 
practice one may be forced to fix at least one of the following 
quantities: n, Nor 2nN. The next theorem, which is proved by Ho 
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(1986~ p~ 34)~ says that the average number of patients (ASN) 
treated before termination of the trial is smaller when a is larger~ 
Theorem 2 Given n~ N and o, the ASN is a monotonically decreasing 
function of a. 
The numerical results in Figure 1 illustrate Theorem 2 for a 
fixed total number of patients 2nN = 120. There are three different 
designs corresponding to N = 1, 2, and 3. The standard deviation a 
is assumed to be known and oranges from -10 to +1a with increment 
.10. It shows that stopping tends to be especially early when o is 
small. For example, if a= .25 and o = _-1a then the trial will 
terminate with probability nearly one at the first interim analysis 
because of a negative result. 
Figure 1 also suggests that given a, o and 2nN, the ASN is a 
monotonically decreasing function of N. This means that there are 
savings in terms of sample size to be gained by having more interim 
analyses. I have not been able to prove this intuitive result; the 
changes in the probabilities of early termination when N and n 
change are not as clear as they are in Theorem 2. I also 
calculated the power of the tests for the cases considered in Figure 
1. Table 6 shows that the power of the test depends on o and on the 
size a, but it is not very sensitive to changes in N if 2nN is 
fixed. The power is exactly the same up to 3 decimal places for N = 
9 
1, 2, and 3. 
TABLE 6 
Values of power given 2nN=120, N=1 or 2 or 3 
a 
.01 .05 • 1 
• 1 .038 ~ 136 .232 
.2 .109 .291 ~426 
.3 .247 ~499 • 641 
.4 ;446 ;708 .818 
{!,/o .5 ;660 ;863 .928 
~6 ;832 ;950 ;978 
;7 ;934 .986 ;995 
.8 .980 .997 .999 
.9 .995 1.000 1.000 
In summary, lower levels of a provide flexibility in choosing N 
but trials with higher. a levels have fewer patients on average and 
have higher power. In choosing N, one has to compromise between the 
group sample size 2n and the power~ based on Tables 2 to 5~ 
6 ~ CONCLUSION 
The one-sided group sequential boundaries proposed here are 
designed for the possibility of stopping a trial early on the basis 
of negative results. It is not proposed as a competitor to the 
procedures proposed previously in the literature since their 
objectives are quite different. For the reasons discussed, the gain 
of periodic review, stopping only for negative results, is obtained 
with virtually no loss in inferential ability. 
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TABLE 2 
Values of~ and required number of patients per group 
with N = 1 (fixed sample size) 
* a b1 1T ~ 2n 
• 01 2~326 .5 2.32 21.6 
.75 3.00 36.0 
.9 3.61 52.1 
.95 3.97 63.1 
.02 2~054 .5 2.05 16~9 
.75 2.1i io.o 
.9 3.3 4.5 
.95 3.10 54.7 
.03 1 ~ 881 .5 1~88 14. 2 
.75 2.56 26.1 
.9 3. 16 40.0 
.95 3.53 49.7 
.04 1. 751 .5 1.z5 12. 3 
• 75 2. 3 2g.5 
.9 3.03 ~ .8 
.95 3.40 6. 1 
.05 1.645 .5 1 ~ 65 10~8 
.75 2.32 21.5 
.9 2.93 
~4-3 
.95 3.29 3.3 
• 1 1 ~ 282 .5 1~28 6~6 
.75 1.96 15. 3 
.9 2.56 26.3 
.95 2.93 34.3 
• 15 1.036 .5 1~04 4~3 
.75 1.71 11.7 
.9 2.~2 21.~ 
.95 2. 8 28. 
.2 ~842 .5 ~84 2~8 
.75 1.52 9.2 
.9 2.12 18.0 
.95 2.49 24.7 
.25 ~675 .5 ~68 1~8 
.75 1.35 7-3 
.9 1.96 15. 3 
.95 2.32 21.5 
* Multiply each value by 02/02 
TABLE 3 
Values of /J. and required number of patients per group; 
for N = 2 and various values of power ,r 
* a b2 1T I!,. 2n 
• 01 2.326 .5 1~65 10~8 
.75 2.12 18.0 
.9 2.55 26.0 
.95 2.81 31.5 
.02 2.054 .5 1.45 8~4 
.75 1.9~ 14.9 
.9 2.~ 22.2 
.95 2. 2 27.4 
.03 1. 881 .5 1.g3 7. 1 
.75 1 • 1 13. 1 
.9 2.24 20.0 
.95 2.49 24.9 
.04 1.751 .5 1 ~ 24 6. 1 
475 1.72 11.8 
.9 2.14 18.4 
.95 2.40 23. 1 
.05 1.645 .5 1 ~ 16 5~4 
.75 1.64 10.8 
.9 2.07 17.1 
.95 2.33 21.6 
• 1 1 ~ 281 .5 • 91 3.3 
.75 1.~8 1.1 
.9 1. 1 13.2 
.95 2.07 17. 1 
• 15 1.035 .5 .73 2.2 
.75 1 • 21 5.9 
.9 1. 64 10.8 
.95 1.90 14. 4 
.2 ~836 .5 ~60 1~4 
.75 1.07 4.6 
.9 1. 51 9. 1 
.95 1.76 12. 5 
.25 .657 .5 ~48 ~9 
.75 .96 3-i 
• 9 1.40 1 • 
.95 1.66 11.0 
* Multiply each value by (12/62 
TABLE 4 
Values of A and required number of patients per group; 
for N = 3 and various values of power 1r 
* ex b3 1T A 2n 
-
• 01 2.326 .5 1.34 7.2 
.75 1.1g 12.0 
.9 2.0 17.4 
.95 2.29 21.0 
.02 2.054 .5 1.19 5.6 
,75 1.58 9,9 
.9 1.9~ 14.8 
.95 2. 1 18 .. 2 
.03 1. 881 .5 1.oi 4.7 
• 75 1 .4 8.7 
.9 1.8~ ~~:~ .95 2.0 
.04 1. 751 .5 1.01 4~1 
.75 1.40 7.8 
.9 1.75 12. ~ 
.95 1.96 15. 
.05 1 ~645 .5 
-9i 3.6 
.75 1 •g 7.2 
.9 1. 9 11. 4 
.95 1.90 14. 4 
• 1 1 ~ 280 .5 ~74 2.2 
.75 1.1 ~ 5. 1 
.9 1. 4 8.8 
.95 1.69 11,5 
• 15 1.029 .5 .6 1. 4 
.75 .99 4.0 
.9 1,35 7.2 
.95 1.56 9,.7 
.2 .820 .5 • 49 1.0 
.75 ,89 i· 1 
.9 1,25 .2 
.95 1.46 8.6 
.25 .621 .5 .40 ~6 
.75 ,80 2.6 
.9 1.18 5.5 
.95 1. 41 7,9 
* Multiply each value by 0 2 10 2 
TABLE 5 
Values of~ and required number of patients per group; 
for N = 4 and various values of power n 
* a b4 '1T ~ 2n 
• 01 2~326 .5 1.16 5.4 
.75 1.50 9.0 
.9 1.81 13. 1 
.95 1.99 15.8 
.02 2.054 .5 1.0~ 4~2 
.75 1.~ 7.4 
.9 1. 7 11 • 1 
.95 1.85 13. 7 
.03 1. 881 .5 .94 g-5 
.75 1.28 .5 
.9 1.58 1 o.o 
.95 1.76 12.4 
~04 1.751 .5 .88 3. 1 
.75 1. 21 5.9 
.9 1.52 9.2 
.95 1.70 11.5 
.05 1.644 .5 .82 2.7 
.75 1 • 16 5.4 
.9 1 .47 8.6 
.95 1.65 1 o. 9 
• 1 1.277 .5 ~64 1.i 
.75 .98 
~:6 .9 1 .29 
.95 1 .47 8.6 
• 15 1. 021 .5 
-~2 1 • 1 
.75 • 6 3.0 
.9 1.17 5.5 
.95 1.36 7.4 
.2 .801 .5 
.4~ 2:4 .75 .1 
.9 1.10 4.8 
.95 1.30 6.8 
.25 .577 .5 .35 .5 
.75 .72 2. 1 
.9 1.07 4.6 
.95 1.30 6.7 
* Multiply each value by a2102 
FIGURE 1 
ASN vs. o/a when 2nN = 120 
1 : N=2, ex=. 01 ; 2: N=2, cx=.05; 3: N=2, a=.25; 
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